133
Participants
Start Date
February 4, 2019
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Biopsy Procedure
Undergo tissue biopsy
Biospecimen Collection
Undergo blood sample collection
Computed Tomography
Undergo CT
Laboratory Biomarker Analysis
Correlative studies
Magnetic Resonance Imaging
Undergo MRI
Olaparib
Given PO
Quality-of-Life Assessment
Ancillary studies
Radium Ra 223 Dichloride
Given IV
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Maryland/Greenebaum Cancer Center, Baltimore
Duke University Medical Center, Durham
Ohio State University Comprehensive Cancer Center, Columbus
Wayne State University/Karmanos Cancer Institute, Detroit
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
Siteman Cancer Center at West County Hospital, Creve Coeur
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
University of Kansas Cancer Center - Lee's Summit, Lee's Summit
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City
University of Kansas Cancer Center - North, Kansas City
University of Kansas Cancer Center, Kansas City
University of Kansas Clinical Research Center, Fairway
University of Kansas Hospital-Westwood Cancer Center, Westwood
University of Kansas Cancer Center-Overland Park, Overland Park
UC San Diego Moores Cancer Center, La Jolla
University of California Davis Comprehensive Cancer Center, Sacramento
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH